Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CStone Pharmaceuticals Co. Ltd.

http://www.cstonepharma.com

Latest From CStone Pharmaceuticals Co. Ltd.

Move Over Roivant, Nuvation: EQRx Reveals Biggest Biopharma SPAC Merger This Year

EQRx has raised at least $750m since it launched in January 2020 and will have $2bn to fund its ongoing development of low-cost drugs after merging with a special purpose acquisition corporation.

Deals Financing

Oncology, Domestic Firms Dominate New China Approvals As Innovation Gathers Pace

China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years. 

China Approvals

EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.

ImmunoOncology Clinical Trials

China Inc. Shines In Latest Batch Of Approvals

Chinese domestic firms have gained a flurry of novel drug approvals at home, including the first globally for an anti-PD-1 antibody for nasopharyngeal carcinoma.

China Approvals
See All

Company Information

UsernamePublicRestriction

Register